The Colorado Prescription Drug Affordability Board (PDAB) selected five prescription drugs for its first affordability reviews at its Aug. 4th meeting.  The drugs and their primary treatments that will enter affordability reviews and be considered for upper payment limits (UPL) are as follows:  Enbrel (rheumatoid and psoriatic arthritis) Genvoya (human immunodeficiency virus) Cosentyx (plaque psoriasis … Read more